

## Overview

### Useful For

Monitoring serum pregabalin (Lyrica) concentrations, assessing compliance, and adjusting dosage in patients

### Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Specimen Required

**Collection Container/Tube:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

#### Collection Instructions:

1. Collect specimen immediately before next scheduled dose.
2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.

### Forms

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

### Specimen Minimum Volume

0.5 mL

### Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	28 days	

	Ambient	28 days	
	Frozen	28 days	

## Clinical & Interpretive

### Clinical Information

Pregabalin (Lyrica) is an anticonvulsant drug used to treat partial seizures in patients and is a more potent successor to gabapentin. Pregabalin is commonly used for neuropathic pain and fibromyalgia. This test can be used by healthcare providers to assess compliance and may be clinically useful in patients with kidney failure who generally require lower dosages. Therapeutic and toxic ranges are not well defined. Therapeutic concentrations are reportedly from 2 to 5 mcg/mL, while toxicity may occur at concentrations above 10 mcg/mL.

### Reference Values

2.0-5.0 mcg/mL

### Interpretation

The serum concentration should be interpreted in the context of the patient's clinical response and other clinical tests. This may provide useful information for patients showing poor response, noncompliance, or adverse effects. Toxicity can occur with concentrations greater or equal to 10 mcg/mL.

### Cautions

This test cannot be performed on whole blood.

### Clinical Reference

1. Baselt R: Disposition of Toxic Drugs and Chemicals in Man. 10th ed. Biomedical Publications; 2014
2. Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. *Pharmacopsychiatry*, 2018 Jan;51(1-02):9-62

## Performance

### Method Description

Samples are extracted with analyte detection by mass spectrometry.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Monday

### Report Available

2 to 7 days

### Specimen Retention Time

---

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

80299

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
PGN	Pregabalin, S	47414-8

Result ID	Test Result Name	Result LOINC® Value
65119	Pregabalin, S	47414-8